Physician

David B Staub, M.D.

According to 2025 Medicare claims, David Staub, M.D. (NPI: 1255319422) practices rheumatology in the Davenport-Moline-Rock Island, IA-IL market, with the plurality of this provider's patient population coming from Scott, IA. This provider's primary affiliated billing organization is RHEUMATOLOGY ASSOCIATES, PC (NPI: 1851578868; TIN: 261643846) and primary practice location at 52722-1624. Staub is affiliated with the IRCCO (ACO ID: A2619) and Genesis Accountable Care Organization, LLC. (ACO ID: A4799), participating under the MSSP model.

Staub's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 397 traditional Medicare patients, billed 93,407 HCPCS/CPT codes, and received $934,915 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,125 prescription claims across 392 beneficiaries totaling $2,680,956 in drug costs, led by Humira(Cf) (Adalimumab). Open Payments data shows 23 records totaling $722. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $801,170 to $2,680,956. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	445	58,852	$1,035,564
2016	412	49,559	$936,632
2017	413	42,602	$1,002,943
2018	425	39,480	$972,076
2019	381	41,902	$811,726
2020	353	69,168	$1,004,589
2021	340	59,813	$853,995
2022	338	52,762	$775,399
2023	352	62,934	$834,286
2024	397	93,407	$934,915

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	286	2,661	$801,170
2016	330	2,755	$927,472
2017	320	2,696	$1,059,661
2018	326	2,861	$1,363,357
2019	342	2,912	$1,527,774
2020	360	3,328	$1,622,323
2021	352	3,065	$1,981,098
2022	358	2,845	$2,346,604
2023	367	2,868	$2,205,249
2024	392	3,125	$2,680,956

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	268	458	$83
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	268	455	$11
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	185	344	$8
82040	Albumin (protein) level	115	212	$5
85651	Red blood cell sedimentation rate, to detect inflammation, non-automated	181	291	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf)	Adalimumab	47	1,316	$320,064
Enbrel Sureclick	Etanercept	37	1,036	$276,708
Humira(Cf) Pen	Adalimumab	39	1,092	$266,694
Rinvoq	Upadacitinib	33	990	$213,140
Cosentyx Sensoready (2 Pens)	Secukinumab	27	756	$213,049

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$722	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David B. Staub, M.D.?

Tedicare shows public-source Medicare data for David B. Staub, M.D. (NPI 1255319422), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David B. Staub, M.D. have ACO affiliation data?

David B. Staub, M.D. is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619) and Genesis Accountable Care Organization, LLC. (MSSP, ACO ID A4799).

What billing organization is linked to David B. Staub, M.D.?

David B. Staub, M.D. is linked to RHEUMATOLOGY ASSOCIATES, PC (billing NPI 1851578868) in the available physician profile data.

Does David B. Staub, M.D. have Open Payments data?

David B. Staub, M.D. has 23 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.